References
- Allen E, Doisy A. An ovarian hormone. JAMA 1923;81:819–21
- Butenandt A. Uber Progynon ein kristallisiertes weibliches Sexualhormon. Naturwissenschaften 1929;17:879
- Allen W, Butenandt A, Corner G, Slotta K. Nomenclature of corpus luteum hormone. Science 1935;16:153
- Gaunt W. A preliminary report on a collaborative assay of conjugated oestrogen preparations. J Am Pharm Assoc 1953;42:173–6
- Utian WH. Pieter van Keep Memorial Lecture. Menopause – a modern perspective from a controversial history. Maturitas 1997;26:73–82
- Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial cancer. N Engl J Med 1975;293:1164–7
- Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin therapy in healthy postmenopausal women. JAMA 2002;288:321–33
- Stuenkel C, Davis S, Gompel A, et al. Treatment of symptoms of menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015;100:3975–4011
- Lumsden MA, Davies M, Sarri G; Guideline Development Group for Menopause: Diagnosis and Management (NICE Clinical Guideline No. 23). Diagnosis and Management of Menopause: The National Institute of Health and Care Excellence (NICE) Guideline. JAMA Intern Med 2016;176:1205–6
- Baber R, Panay N, Fenton A, et al. 2016 IMS Recommendations on women’s midlife health and menopausal hormone therapy. Climacteric 2016;19:109–50
- De Villiers T, Hall J, Pinkerton J, et al. Global Consensus Statement on Menopausal Hormone Therapy. Climacteric 2016;19:313–15